Close

Roche – Biogen Settle US Patent Law Suit For Arthritis Drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Based on a filing on October 23 in Massachusetts federal court, Roche, the Swiss pharmaceutical giant, has reached a settlement in a patent lawsuit against Biogen, which happens to be a U.S. biotech firm. The lawsuit was concerning Biogen’s biosimilar variant of Roche’s incredibly successful rheumatoid arthritis drug, Actemra.

Roche, along with its affiliates, Genentech as well as Chugai Pharmaceutical, apprised the court that they have gone on to reach a settlement agreement with Biogen and its manufacturer, Bio-Ther. 

Biosimilars happen to be similar versions of biologic drugs that can be compared to generics of traditional small-molecule drugs. Complex biologic drugs, unlike traditional drugs, originate from living cells and thereby cannot be replicated to the T.

According to Roche’s report, the company went on to earn more than 2.7 billion Swiss francs, which is equivalent to over $3 billion from the global sales of its biologic drug Actemra in 2022. Sales of Actemra had decreased by 22% in 2021 due to a decline in demand for the drug as part of the treatment for COVID-19.

In September, the U.S. Food and Drug Administration gave its nod to Biogen’s Tofidence, which happens to be the first biosimilar to Actemra to have received the approval. In July, Roche filed a lawsuit claiming that the biosimilar would violate numerous patents linked to the production as well as utilisation of its biologic drug.

Latest stories

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back